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A B S T R A C T
Peroxisome proliferator-activated receptor (PPAR)g stimulation provides protection in severalmodels of
neurological disorders, but the mechanisms underlying these effects remain to be fully elucidated. Here
we have studied whether two PPARg agonists, pioglitazone and rosiglitazone, prevent loss of
differentiated SH-SY5Y cells transiently exposed to glucose deprivation (GD). Nanomolar drug
concentrations prevented GD-induced cell loss in a concentration- and time-dependent manner. These
effects were abolished by malonate, a reversible mitochondrial Complex II inhibitor, while significantly
potentiated by pyruvate, thus suggesting that they are related to mitochondrial function. During cell
pretreatment, PPARg agonists promoted biogenesis of functional mitochondria, as indicated by the up-
regulation of PPARg coactivator (PGC)-1a, NRF1, TFAM, cytochrome c oxidase subunit (CO) I and CO IV,
and the increased level ofmtDNA,while did not significantly changemitochondrialmembrane potential.
In addition, the analysis of the concentration–response and time-course curves for the protective effects
and the up-regulation of mitochondrial biogenesis markers suggests that mitochondrial biogenesis and
cell loss prevention are related effects. In conclusion our data indicate that a prolonged PPARg
stimulation, by repeated administration of nanomolar pioglitazone or rosiglitazone concentrations,
decreases GD-induced loss of differentiated SH-SY5Y cells. In addition, they suggest that mitochondrial
biogenesis may contribute to these effects.
 2009 Elsevier Ltd. All rights reserved.
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Peroxisome proliferator-activated receptors (PPARs) are mem-
bers of the nuclear receptor superfamily. Three PPAR isoforms (a,
b/d and g), which are encoded by three distinct genes, have been
characterized both in rodents and in humans (Berger and Moller,
2002). Among PPAR, PPARg is a pharmacological target of
particular interest. PPARg stimulation enhances sensitivity of
peripheral tissues to insulin and two synthetic PPARg agonists,
pioglitazone and rosiglitazone, are currently approved by both FDAAbbreviations: ALS, amyotrophic lateral sclerosis; atRA, all-trans retinoic acid; BSS,
bicarbonate-buffered balanced salt solution; CO I, cytochrome c oxidase subunit I;
CO IV, cytochrome c oxidase subunit IV; DMEM/F12, Dulbecco modified Eagle’s
medium/Nutrient Mixture Ham’s F12; FCS, fetal calf serum; GD, glucose
deprivation; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide;
PBS, Mg2+-free phosphate-buffered saline; PD, Parkinson’s disease; PGC-1a,
peroxysome proliferator-activated receptor g coactivator-1a; PPAR, peroxisome
proliferator-activated receptor; SDH, succinate dehydrogenase.
* Corresponding author. Tel.: +39 011 6707955; fax: +39 011 6707688.
E-mail address: gianluca.miglio@unito.it (G. Miglio).
0197-0186/$ – see front matter  2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2009.05.001and EMEA for the treatment of Type 2 diabetes (Yki-Ja¨rvinen,
2004).
A growing body of evidence indicates that PPARg stimulation
might exert further beneficial effects. PPARg is expressed in several
regions of the adult CNS including piriform cortex, basal ganglia
and dentate gyrus, both in neuronal and non-neuronal cells
(Moreno et al., 2004; de la Monte and Wands, 2006). Moreover, it
has been demonstrated that PPARg agonists reduce neuronal cell
loss in in vitro models of neurotoxicity (Aoun et al., 2003; Zhao
et al., 2006; Jung et al., 2007; Fuenzalida et al., 2007) and in in vivo
models of cerebral ischemia-reperfusion injury (Culman et al.,
2007), Parkinson’s disease (PD; Breidert et al., 2002; Dehmer et al.,
2004) and amyotrophic lateral sclerosis (ALS; Kiaei et al., 2005;
Schu¨tz et al., 2005). However, at cellular level, the mechanisms
underlying these effects are not fully understood. Part of themhave
thought to be related to the ability of these drugs to regulate gene
expression in neuronal cells. For example, it has been shown that
pioglitazone reduces the harmful induction of cyclooxygenase-2 in
response to oxidative injury in primary cortical neurons (Zhao
et al., 2006), rosiglitazone induces the expression of antioxidative
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neuroblastoma cells (Jung et al., 2007) and of the anti-apoptotic
protein Bcl-2 in PC12 cells (Fuenzalida et al., 2007). Nevertheless, it
is reasonable that further actions could contribute to the PPARg-
mediated neuroprotective effects.
It has been demonstrated that PPARg stimulation, through the
induction of the PPARg coactivator (PGC)-1a, promotes mitochon-
drial biogenesis and remodeling in several peripheral tissues such
as adipose and muscle tissues (Puigserver et al., 1998; Wu et al.,
1999; Puigserver and Spiegelman, 2003; Pagel-Langenickel et al.,
2008). Similar effects have been recently shown in the brain of
mice and in the NT-2 human neuronal-like cells after prolonged
exposure to rosiglitazone or pioglitazone, respectively (Strum
et al., 2007; Ghosh et al., 2007). Mitochondrial biogenesis has been
proposed to contribute to the effects of PPARg agonists in diabetic
patients (Wilson-Fritch et al., 2004; Rong et al., 2007; Pagel-
Langenickel et al., 2008). Though, to date, there is no evidence that
it also contributes to the PPARg-mediated neuroprotective effects.
Here we have evaluated, in vitro, whether pioglitazone and
rosiglitazone reduce neuronal cell loss induced by transient
glucose deprivation (GD) and how mitochondrial biogenesis
contribute to this effect. For these purposes, we have employed
differentiated SH-SY5Y human neuroblastoma cells. These cells
have been already employed as cellular model to study GD-
induced neuronal cell death (Russo et al., 2004; Ko¨gel et al., 2006;
Kobayashi et al., 2007). Interestingly, they express PPARg
(Valentiner et al., 2005), thus representing a valuable cellular
model to study the protective effects that follow PPARg
stimulation.
2. Materials and methods
2.1. Drugs and chemicals
Dulbecco modified Eagle’s medium/Nutrient Mixture Ham’s F12 (1:1) (DMEM/
F12), and fetal calf serum (FCS) were from Lonza (Milan, Italy). Tetramethylrho-
damine ethyl ester (TMRE) was from Molecular Probe (Milan, Italy). Rosiglitazone
was from Alexis (Vinci, Italy). Pioglitazone, malonic acid, L-glutamine, penicillin,
pyruvate, streptomycin, all-trans-retinoic acid (atRA), and all other reagents were
from Sigma–Aldrich (Milan, Italy). Pioglitazone, rosiglitazone and atRA were
dissolved in dimethylsulfoxide, all other drugs were dissolved in the experimental
buffers. Final drug concentrations were obtained by dilution of stock solutions in
the experimental buffers. Final concentration of organic solvent was always less
than 0.1% (vol/vol), it has no effects on cell viability and cells exposed to vehicle
alone were considered as controls.
2.2. Cell cultures
SH-SY5Y human neuroblastoma cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and were cultured in DMEM/F12
supplementedwith 10% (vol/vol) FCS, penicillin (100 IU/ml), streptomycin (100mg/
ml) and L-glutamine (2 mM). Cell culture medium was replaced every 2 days and
the cultures were maintained at 37 8C in a 95% (vol/vol) air–5% (vol/vol) CO2
humidified incubator. Cells were used up to the 15th passage and were
differentiated by treatment with atRA (5mM) added to cell culture medium every
2 days for 5 days (Zimmermann et al., 2004). The day before the experiment, cells
were plated in 24- or 6-well culture plates (0.5–0.8 x 106 cells/well, respectively).
2.3. Cell treatments and in vitro model of GD-induced neuronal cell loss
To study the protective effects of pioglitazone and rosiglitazone we used the
experimental protocol shown in Fig. 1 of supplemental material. Cells were
pretreated for 5 days with either pioglitazone or rosiglitazone (simultaneously with
atRA). After a 24-h washout, cells were either transiently glucose-deprived (2 h),
exposed to malonate (10 mM; 1.5 h) or glucose-deprived in the presence of
malonate (1 h). The protective effects of the PPARg agonists were measured at the
end of a 24–72-h recovery period. In some experiments pyruvate (5 mM)was added
during the recovery period (see Section 3 for details). GD was performed as
described by Suh et al. (2007a). Briefly, the culture medium was exchanged with a
bicarbonate-buffered balanced salt solution (BSS; in mM: 134, NaCl; 15.7, NaHCO3;
3.1, KCl; 1.2, CaCl2; 1.2, MgSO4; 0.25, KH2PO4). The pH was adjusted to 7.2 and the
solution was equilibrated with 5% (vol/vol) CO2 at 37 8C. After a 5-min period to
allow complete regression of glucose from the cells, the culture medium was
completely exchanged a second time and cultures were placed at 37 8C in a 95%(vol/vol) air–5% (vol/vol) CO2 humidified incubator. Control wells received BSS
supplemented with 10 mM glucose. GD was terminated at the designated time
points by replacing BSS with standard medium.
Cell loss was evaluated by measuring both cell viability and cell number at the
end of the recovery period. Cell viability was determined by measuring the
succinate dehydrogenase (SDH) activity by the MTT assay (Mosmann, 1983). Cell
number was determined by counting the viable cells in a hemacytometer by the
trypan blue exclusion test, blind by an observer.
2.4. Western blot analyses
Cell culture plates were washed with Mg2+-free phosphate-buffered saline (PBS)
beforeaddingan ice-cold lysisbuffer [20 mMTris–HClpH7.5, 150 mMNaCl,0.1%(wt/
vol) sodium dodecyl sulphate, 1% (vol/vol) Triton X-100, 1% (wt/vol) sodium
deoxycholate, 5 mM EDTA] supplemented with 1ml/ml of a protease inhibitors
cocktail (Sigma–Aldrich), 0.1 mM ZnCl2, and 1 mM phenylmethylsulphonyl fluoride.
Cell lysates were centrifuged at 18,000  g for 15 min and the supernatants were
recovered. The protein concentration of cell lysates was determined using the BCA
protein assay (Pierce Biotechnology, Inc., Rockford, IL, USA) following the
manufacturer’s instruction. Samples containing 75mg of protein were subjected to
SDS-polyacrylamide gel electrophoresis using an 8 or 12% (wt/vol) gel for either PGC-
1a and PPARg or cytochrome c oxidase subunit I (CO I) and IV (CO IV), respectively.
Proteins were blotted to a polyvinylidene difluoride membrane (Millipore, Bedford,
MA, USA) which were then incubated with SuperBlock blocking buffer (Pierce). PGC-
1a was detected following incubation, with a goat polyclonal antibody (Santa Cruz
Biotechnology, Inc., CA, USA) diluted 1:200 in PBS containing 0.1% (vol/vol) Tween-20
(PBS-T) overnight at 4 8C. PPARg was detected following incubation, with a rabbit
polyclonal antibody (Santa Cruz) diluted 1:200 in PBS-T for 1 h at room temperature.
COIandCOIVweredetectedfollowing incubationwithmousemonoclonal antibodies
(Santa Cruz and Abcam plc Cambridge Science Park, Cambridge, UK, respectively)
diluted 1:1000 in PBS-T overnight at 4 8C. The secondary antibodieswere horseradish
peroxidase-conjugated donkey anti-goat IgG (1:14,000; Santa Cruz), donkey anti-
rabbit IgG(1:10,000; SantaCruz) andsheepanti-mouse IgG(1:10,000; SantaCruz). To
confirm the homogeneity of the proteins loaded, the membranes were stripped and
incubated with an anti-b-actin monoclonal antibody (1:2500, Santa Cruz). The
membranes were overlaid withWestern Lightning Chemiluminescence Reagent Plus
(PerkinElmer Life Science, Cetus, Norwalk, CT, USA) and then exposed to Hyperfilm
ECL film (Amersham Biosciences Corp., Piscataway, NJ, USA). Protein bands were
quantified on film by densitometry, using the software Gel-Pro Analyzer 4.5, 2000
(Media Cybernetics Inc., Leiden, The Netherlands).
2.5. mtDNA extraction and quantification
mtDNA was extracted and analyzed as described by Nisoli et al. (2003) with
minormodifications. Aliquots of mtDNAwere loaded on ethidium bromide-stained
agarose gel [1.5% (wt/vol)] and signals were analyzed by the densitometric analysis
software NIH Image J 1.41 (National Institutes of Health, Bethesda, MD, USA).
2.6. RT-PCR analysis
Total RNAwas extracted from cultured cells by using Omnizol (Euroclone, Milan,
Italy). Resulting mRNA was reverse-transcribed by using the RevertAid HMinus
Synthesis kit and oligo(dT)18 primers (Fermentas Life Science, Milan, Italy) for 1 h at
42 8C. Reactions were terminated by heating the mixtures at 70 8C for 10 min. The
resulting cDNA was used as a template for PCR amplifications. PCR amplifications
were performed in 50ml reaction mixtures containing 2.0–4.0 ml of cDNA, 5.0 ml of
10 buffer, 1.5 ml of 50 mM MgCl2, 0.5ml of 2 mM dNTPs mix, 2 U of Taq DNA
polymerase (Fermentas Life Science), and 5.0 nM of each primer (SigmaGenosys;
Table 1, Supplemental material). PCR amplicons were resolved in an ethidium
bromide-stained agarose gel [1.5% (wt/vol)] by electrophoresis, and signals were
quantified by the analysis software (NIH Image J 1.41). Data are expressed as the
ratio of the signal obtained for each gene in one sample divided by that obtained for
the reference gene (b-actin) in the same sample.
2.7. Measurement of mitochondrial membrane potential
The mitochondrial membrane potential was measured with the fluorescent
probe TMRE as previously described (Rao and Norenberg, 2004) with minor
modification. Briefly, cells were loaded with TMRE in standard fresh medium at a
final concentration of 50 nM for 30 min. Emitted fluorescence was examined on a
Leica inverted microscope equipped with multivariant fluorescent filters. The
fluorescence emissionwas recorded at 590 nm. Randomfieldswith a similar degree
of cell density in each experimental group were captured with an air cooled digital
camera and fluorescence intensity from each cell (30–40 cells/group) was analyzed
using NIH Image J 1.41 software.
2.8. Data analysis
Results are expressed as means  S.E.M. of at least three experiments. Statistical
significance was evaluated by one-way ANOVA followed by the post hoc Dunnet’s test.
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sigmoidal concentration–response or time-response curves and analyzed with a four-
parameter logistic equation using the software Origin 6.0 (Microcal Software,
Northampton, MA, USA). EC50 and ET50 were the molar concentration of drug that
exerts 50% of the maximal effect and the time required to produce 50% of the maximal
effect produced by pioglitazone (100 nM).
3. Results
3.1. PPARg expression in SH-SY5Y neuroblastoma cells
It has been reported that several human neuroblastoma cell
lines, including SH-SY5Y line, express PPARg (Valentiner et al.,
2005). To investigate whether our clone expresses this receptor
and how either cell differentiation or PPARg stimulation changes
its expression level, we carried out Western blot analyses of cell
extracts prepared from cells exposed to either atRA alone (5 mM, 5
days) or pioglitazone (100 nM, 1–5 days) plus atRA. A single band
at 55 kDa was detected in untreated cells. As expected for a PPARg
agonist (Kim et al., 2003), pioglitazone gradually and significantly
increased PPARg expression level and on day 5 it was 1.49  0.06-
fold over pioglitazone-untreated cells (p < 0.01; n = 4) (Fig. 1A).Fig. 1. Expression of PPARg in SH-SY5Y cells. SH-SY5Y human neuroblastoma cells
were treated with either pioglitazone (100 nM; 1–5 days) plus atRA (5 mM) (A),
rosiglitazone (10 nM, 5 days) plus atRA or atRA alone (5 days) (B). PPARg expression
was evaluated by Western blot analysis; b-actin was used as internal control.
Pictures shown are representative of three to four independent experiments and
data are means  S.E.M. **p  0.01 vs. untreated cells (day 0).Similarly, rosiglitazone (10 nM, 5 days) significantly up-regulated
PPARg expression (1.45  0.10-fold over rosiglitazone-untreated
cells; p < 0.01; n = 3; Fig. 1B). In contrast, neither atRA nor vehicle
alone changed the PPARg expression level (Fig. 1B). Notably, GD (see
below) did not change PPARg expression level (data not shown).
These data indicate that differentiated SH-SY5Y neuroblastoma
cells can be a valuable model to study the PPARg-mediated effects
on neuronal cells.
3.2. Effects of PPARg agonists on GD-induced neuronal cell loss
To investigate whether PPARg stimulation could prevent
neuronal cell death due to impairment of cellular energetic
homeostasis, we studied the effects of cell pretreatment with
either pioglitazone or rosiglitazone on GD-induced neuronal cell
loss. GD (2 h) significantly decreased cell viability (52.6  4.8%,
compared to control cells; p < 0.01; n = 6; Fig. 2A). Pioglitazone and
rosiglitazone (10 pM to 1 mM, 5 days) significantly prevented this
effect in a concentration-dependent manner with a maximum at 100
and 10 nM (78.9  9.4% and 80.0  9.5% over glucose-deprived cells;
p < 0.01; n = 6; Fig. 2A), respectively; the EC50s calculated were
5.1  1.2 and 0.6  0.2 nM, respectively. The protective effects
exerted by the two PPARg agonists increased in a time-dependent
manner; they were significant on day 3 (p < 0.05; n = 4) andmaximal
on days 4–5 (p < 0.01; n = 4; Fig. 2B). Notably, cell pretreatment with
either pioglitazone (100 nM, 5 days) or rosiglitazone (10 nM, 5 days)
only slightly increased basal SDH activity (+13.0  16.8% and
+5.8  9.8% compared to control cells, respectively; n = 4), thus
indicating that the protective effects we observed does not depend
either on the increased basal SDH activity or on cell proliferation.
Since MTT assay provides an indirect measure of cell loss we
confirmed the above results by determining the number of viable cells
at the end of the experiments. GD (2 h) produced a 51.8  11.1% of cell
loss that was significantly prevented by either pioglitazone (100 nM;
5 days) or rosiglitazone (10 nM; 5 days): 76.8  13.8% and
78.5  16.3% over glucose-deprived cells, respectively (p < 0.01;
n = 3; Fig. 2C).
These results show that prolonged PPARg stimulation, by
repeated administration of nanomolar concentrations of either
pioglitazone or rosiglitazone, decreases GD-induced loss of
differentiated SH-SY5Y neuroblastoma cells.
3.3. Effects of PPARg agonists on PGC-1a expression and function in
SH-SY5Y cells
Since, it has been shown that PPARg stimulation up-regulated
PGC-1a in a variety of cell types (Wu et al., 1999; Hondares et al.,
2006), including neuronal cells (Strum et al., 2007; Ghosh et al.,
2007), we hypothesized that the protective effects we observed
could be related to the induction of this protein. To test our
hypothesis, first, we exposed SH-SY5Y cells to pioglitazone
(100 nM; 1–5 days) and measured the expression of PPARGC1A
gene. As depicted in Fig. 3A, untreated cells showed a low basal
expression of this gene. Drug administration significantly modu-
lated PPARGC1A expression: PPARGC1A peaked at 24 h (mean
1.85  0.15-fold over basal level; p < 0.01; n = 4) and returned near
the basal level (mean 1.23  0.10-fold over basal level) 48 h after each
pioglitazone administration. Western blot analysis showed that
pioglitazone progressively and significantly increased PGC-1a
expression with the maximum on days 4–5 (1.43  0.07-fold over
control cells; p < 0.01; n = 4, Fig. 3B). Moreover, pioglitazone (10 pM
to 1 mM; 5 days) increased PGC-1a expression level in a concentra-
tion-dependent manner with the maximum (+1.39  0.06-fold over
control cells; p < 0.01; n = 4; Fig. 3C) at 100 nM; the EC50 calculated
was 3.9  3.3 nM. Similarly, rosiglitazone (10 nM) significantly
up-regulated PGC-1a expression level, and on day 5 it was
Fig. 2. Effects of PPARg agonists on GD-induced cell loss. (A) Concentration–response curves of the effects of pioglitazone and rosiglitazone on GD-induced decrease of cell
viability. SH-SY5Y cells were untreated (vehicle alone) or treated with either increasing pioglitazone or rosiglitazone concentrations (10 pM to 1mM) for 5 days before GD.
Cell viability was measured at the end of the experiment by using the MTT assay. (B) Time-course of the effects of pioglitazone and rosiglitazone on GD-induced decrease of
cell viability. SH-SY5Y cells were untreated or pretreated with either pioglitazone (100 nM) or rosiglitazone (10 nM) for 1–5 days (black arrow indicates drug replacement).
Cell viability wasmeasured at the end of the experiment by using theMTT assay. (C) Effects of pioglitazone and rosiglitazone on cell number. SH-SY5Y cells were untreated or
pretreated with either pioglitazone (100 nM; 5 days) or rosiglitazone (10 nM; 5 days). Cell number was determined by counting the cells in a hemacytometer under
microscope and using trypan blue dye to exclude dead cells. Data aremeans  S.E.M. of three to four experiments run in triplicate. *p  0.05; **p  0.01 vs. glucose-deprived cells.
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these experiments no significant effect was exerted by either atRA
(5 mM, 5 days) or vehicle alone (Fig. 3D). Second, to assess the
transcriptional consequences of PGC-1a induction, we measured the
expression level of genes known to be induced in response to PGC-1a
up-regulation. As shown in Fig. 3E, semiquantitative RT-PCR analysis
showed that both pioglitazone (100 nM; 5 days) and rosiglitazone
(10 nM; 5 days) significantly up-regulated the expression of both
NRF1 (+1.35  0.15-fold and +1.38  0.11-fold, respectively, over
control cells; p < 0.05; n = 4) and TFAM (+1.43  0.07-fold and
+1.45  0.15-fold, respectively, over control cells; p < 0.05; n = 4)
and induced the expression of UCP-2 (+2.74  0.48-fold and
+3.01  0.39-fold over control cells; p < 0.01; n = 4).
These data indicate that in SH-SY5Y cells PPARg stimulation
promotes the activation of the PGC-1a-dependent genes.
3.4. Effects of pioglitazone on mitochondrial biogenesis in SH-SY5Y
cells
It has been reported that PPARg stimulation, together with PGC-
1a, promotesmitochondrial biogenesis (Wu et al., 1999; Puigserver
and Spiegelman, 2003). Therefore, we investigate whether PPARg
stimulation promotes similar effects in SH-SY5Y neuronal-like cells.
In addition, since the similarity of the effects exerted by the twoPPARg agonists, we decided to perform the following experiments
using only pioglitazone. First, we studied the effects of this drug on
the expression level of CO I and CO IV (mtDNA- and nuclear DNA-
encodedmitochondrial protein, respectively) recognizedmarkers of
mitochondrial cell content. As shown in Fig. 4A, pioglitazone
(100 nM) significantly increased both CO I and CO IV expression in a
time-dependent manner with a maximum on day 5 (+1.70 0.10,
+1.51  0.10 over control cells, respectively; p < 0.01; n = 4). These
effectswere concentration-dependent in the range 10 pMto 1 mM; the
maximums were at 100 nM (+1.70  0.07 and +1.48  0.05 over
control cells, respectively; p < 0.01; n = 4) while the EC50s calculated
were 2.3 0.9 and 4.5 2.7 nM for CO I and CO IV, respectively
(Fig. 4B). Second, wemeasured the amount of mtDNA, another marker
ofmitochondrial cell content (Nisoli et al., 2003). As shown in Fig. 4C, in
comparison to control cells, pioglitazone (100 nM; 5 days) significantly
increased the amount of mtDNA (+1.63 0.08-fold over control cells;
p < 0.01; n = 4; Fig. 4C). Finally, to assess whether pioglitazone affects
mitochondrial function, we assessed mitochondrial membrane poten-
tial in pioglitazone-treated and -untreated cells. In comparison to
vehicle, pioglitazone (100 nM, 5 days) did not significantly change
mitochondrial membrane potential (Fig. 4D).
These results consistently indicate that in SH-SY5Y neuroblas-
toma cells PPARg stimulation promotes biogenesis of functional
mitochondria.
Fig. 3. Effects of PPARg agonists on PGC-1a expression. (A) Time-course of the effect of pioglitazone on PPARGC1A expression. SH-SY5Y cells were untreated or treated with
pioglitazone (100 nM) for 1–5 days; PPARGC1A expression was evaluated by semiquantitative RT-PCR analysis by using a specific primer pair andb-actin as a reference gene.
(B) Time-course of the effect of pioglitazone on PGC-1a expression. SH-SY5Y cells were untreated or treatedwith pioglitazone (100 nM) for 1–5 days; PGC-1a expressionwas
evaluated byWestern blot analysis;b-actin was used as internal control. (C) Concentration–response curve of the effect of pioglitazone on PGC-1a expression. SH-SY5Y cells
were untreated or treated with increasing pioglitazone concentrations (10 pM to 1 mM) for 5 days. PGC-1a expression was measured as above described. (D) Effects of atRA
and rosiglitazone on PGC-1a expression. SH-SY5Y cells were untreated (vehicle) or treated with atRA alone (5 mM; 5 days) or rosiglitazone (10 nM; 5 days). PGC-1a
expressionwasmeasured as above described. (D) Effects of pioglitazone and rosiglitazone on the expression of genes responsive to PGC-1a up-regulation. SH-SY5Y cells were
untreated or treated with either pioglitazone (100 nM; 5 days) or rosiglitazone (10 nM; 5 days).NRF1, TFAM and UCP-2 expression was evaluated by semiquantitative RT-PCR
analysis by using specific primer pairs and b-actin as a reference gene. The pictures shown are representative of three to four independent experiments. Data are
means  S.E.M. of three to four independent experiments. *p  0.05; **p  0.01 vs. untreated cells (day 0).
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To verify whether the protective effect of pioglitazone depend
on mitochondrial function, we investigated how malonate, a
reversible mitochondrial Complex II inhibitor, extensively
employed both in vitro and in vivo as tool to inhibit mitochondrial
energy metabolism (Beal et al., 1993; Gomez-Lazaro et al., 2007),
affects this effect. In particular, we used the same experimental
protocol showed in Fig. 1 supplemental material and to avoid
misinterpretation due to the severity of the insult, we calibrated
the treatment regimen to obtain a level of cell loss similar (50%)
to that described in Fig. 2A and B. Cell exposure to malonate
(10 mM) with (1.5 h) or without glucose (1 h) decreased cellviability (53.0  7.8% and 45.3  4.8%, respectively) and cell
number (53.3  10.1% and 56.3  11.2%, respectively). Pioglita-
zone (100 nM; 5 days) was unable to prevent malonate-induced cell
loss either in the presence or in the absence of glucose, thus
suggesting that its protective effect requires functionally active
mitochondria.
3.6. Effects of pioglitazone on the pyruvate protective effect
In cells exposed to malonate in the absence of glucose,
respiration is inhibited and glycolisis is restricted. In such
conditions, pyruvate addition spares glycolisis and restores
respiration (Kauppinen and Nicholls, 1986). Therefore, to further
Fig. 4. Effects of pioglitazone onmitochondrial biogenesis. (A) Time-course of the effect of pioglitazone on CO I and CO IV expression. SH-SY5Y cells were untreated or treated
with pioglitazone (100 nM) for 1–5 days. CO I and CO IV expression was evaluated by Western blot analysis; b-actin was used as an internal control. (B) Concentration–
response curves of the effect of pioglitazone on CO I and CO IV expression. SH-SY5Y cells were untreated or treated with increasing pioglitazone concentrations (10 pM to
1mM) for 5 days. CO I and CO IV expressionweremeasured as described above. (C)mtDNA amount in pioglitazone (100 nM, 5 days)-treated and -untreated (vehicle) cells. (D)
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protective effect of pioglitazone, we assessed the time-course of
drug effect on GD plus malonate-induced cell death in the absence
or presence of pyruvate (5 mM), added during the recovery period.
In untreated samples, cell loss gradually increased: 54.8  3.8%,
73.7  6.6% and 77.6  4.4% at 24, 48 and 72 h of the recovery period,
respectively (Table 1). Pioglitazone decreased, albeit not significantly,
cell loss (2.8  2.5%, 8.7  5.0% and 9.4  5.5%, at 24, 48 and
72 h, respectively, Table 1). Differently, pyruvate significantly
protected cells against GD plus malonate and cell loss was reduced
by 21.2  2.2%, 30.6  5.2% and 29.9  4.0%, at 24, 48 and 72 h,
respectively (p < 0.01 in comparison to untreated cells; n = 4;
Table 1). Moreover, in pioglitazone pretreated cells a significantly
greater decrease of cell loss was measured (37.8  4.4%, 48.5  3.4%Table 1
Effects of pioglitazone on the protective effect of pyruvate.
Time after GD (h) Cell number  105 (cell loss %)
Pyruvate
Pioglitazone +Pioglitazone
24 3.6  0.3 (54.8  3.8) 3.9  0.2 (52.0 
48 2.1  0.5 (73.7  6.6) 2.8  0.4 (65.0 
72 1.8  0.4 (77.6  4.4) 2.6  0.4 (68.2 
SH-SY5Y cells were untreated or pretreated with pioglitazone (100 nM; 5 days) and exp
was added during the recovery period. Cell number was determined at the end of the re
a p < 0.01 vs. pyruvate-untreated cells.
b p < 0.01 vs. pioglitazone- and pyruvate-untreated cells.and 50.2  4.7%, at 24, 48 and 72 h, respectively p < 0.01 in
comparison to cells treated with pyruvate alone; n = 4; Table 1),
thus indicating that restoration of cell respiration by pyruvate
reduced GD plus malonate-induced cell loss and this effect is
significantly potentiated by pioglitazone pretreatment.
These data further confirm the hypothesis that mitochondrial
biogenesis may contribute to the protective effect exerted by
pioglitazone.
4. Discussion
Results here reported show that prolonged cell exposure to
PPARg agonists prevents GD-induced cell loss and suggest that
mitochondrial biogenesis may contribute to this effect.+Pyruvate
Pioglitazone +Pioglitazone
2.5) 5.2  0.2a (33.6  2.2) 6.6  0.3 (17.0  4.4)a,b
5.0) 4.6  0.4a (43.1  5.2) 5.9  0.3 (25.2  3.4)a,b
5.5) 4.1  0.3a (47.7  4.0) 5.7  0.4 (27.4  4.7)a,b
osed to malonate (10 mM, 1 h) in the absence of glucose (10 mM). Pyruvate (5 mM)
covery period. Data are means  S.E.M. of at least four experiments run in triplicate.
Table 2
Summary of the effects exerted by pioglitazone.
Effect EC50 (nM)
a ET50 (days)
b
Protective effect against GD 5.1  1.2 2.9  0.5
PGC-1a up-regulation 3.9  3.3 2.5  0.3
CO I up-regulation 2.3  0.9 2.5  0.1
CO IV up-regulation 4.5  2.7 3.3  1.3
a EC50 was determined after 5 days of cell pretreatment with increasing
pioglitazone concentrations (10 pM to 1mM).
b ET50 was determine on cells exposed to 100 nM pioglitazone for 1–5 days.
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effects in several in vitromodels of neurotoxicity. Our results are in
agreement and extend these findings showing that cell pretreat-
ment with either pioglitazone or rosiglitazone prevents loss of
differentiated SH-SY5Y cells induced by GD. Both drugs were
equally effective in preventing cell loss, while, as expected,
rosiglitazone resulted more potent than pioglitazone (Willson
et al., 1996). These results indicate that PPARg stimulation
underlies the protective effects. It has also been reported that
pioglitazone may exert PPARg-independent actions. Indeed, this
drug activates not only PPARg but also PPARa (albeit at higher
concentrations; Sakamoto et al., 2000), binds mitoNEET (Colca
et al., 2004) a 2Fe–2S mitochondrial protein and stabilizes this
protein against iron–sulfur cluster release (Paddock et al., 2007).
However, we did not detect PPARa in our cell model (data not
shown), thus the activation of this receptor does not seem to be
necessary to explain the pioglitazone protective effects we
observed. On the other hand, to date, the role of mitoNEET as
pioglitazone receptor, although cannot be excluded (even in our
model), remain largely elusive and need further investigation.
Interestingly, in our experiments pioglitazone and rosiglitazone
exerted protective effects at nanomolar concentrations. Pharma-
cokinetic studies have shown that in diabetic patients the mean
serum concentrations of pioglitazone and rosiglitazonewere in the
low micromolar range (Budde et al., 2003; Niemi et al., 2004). In
addition, studies in animals have documented that these drugs
passes (albeit poorly) the blood–brain barrier (Maeshiba et al.,
1997). Thus, these data suggest that the concentrations effective in
our in vitro model are comparable to that reached in vivo.
Consistent results we obtained when cell viability and cell
number were measured, thus indicating that effectively pioglita-
zone and rosiglitazone decreased GD-induced cell loss. Details on
the events implicated in GD-induced neuronal cell loss have been
previously reported (Suh et al., 2007b). GD primarily impairs
energetic homeostasis (i.e., ATP production from glycolisis and
mitochondria) (Ballesteros et al., 2003; Russo et al., 2004) and
secondarily triggers several events (i.e. production of reactive
oxygen species, increase in intracellular Ca2+ level, activation of
PARP-1) that can result in cytotoxicity (Suh et al., 2007a,b).
Impairment of energetic homeostasis is a major cause of neuronal
cell loss associated to hypoglycaemia and ischemia. In addition, it
contributes to neuronal dysfunction and death observed in many
other neurological disorders (Beal, 2005). Thus, our results,
although preliminary, might be relevant to understand the cell
protective effects exerted by PPARg agonists. Previous studies have
provided evidence that at cellular level PPARg agonists exert
protective effects through multiple mechanisms of action. Dello
Russo et al. (2003) have previously shown that pioglitazone
protects astrocytes against hypoglycaemic-induced cell death after
just 24 h by enhancing glucose utilisation, through the increased
glucose membrane transport. Here we propose an additional
mechanism. During cell pretreatment repeated administration of
PPARg agonists increases PGC-1a expression. This finding is in
agreement with previous data showing that these drugs induce
PGC-1a expression both in non-neuronal, neuronal and neuronal-
like cells (Puigserver et al., 1998; Wu et al., 1999; Puigserver and
Spiegelman, 2003; Strum et al., 2007; Ghosh et al., 2007; Pagel-
Langenickel et al., 2008) and with the recent demonstration that
PPARGC1A is a PPARg-target gene (Hondares et al., 2006). Acting as
a ‘‘transcriptional booster’’, PGC-1a increases the expression of
nuclear genes involved in determining mitochondrial biogenesis
(i.e. TFAM) and remodeling (i.e. UCP-2) (Puigserver et al., 1998;Wu
et al., 1999; Puigserver and Spiegelman, 2003; St-Pierre et al.,
2006). In our model both pioglitazone and rosiglitazone signifi-
cantly increased the expression of NRF1, TFAM, UCP-2. In addition,
we show that pioglitazone significantly increased CO I, CO IVexpression level and the amount of mtDNA, thus indicating that
drug pretreatment promoted mitochondrial biogenesis and
remodeling in SH-SY5Y cells. Interestingly, the analysis of the
time-course and the concentration–response curves for the
protective effects and the up-regulation of both PGC-1a, CO I
and CO IV, indicates that cell protection and mitochondrial
biogenesis are related effects (Table 2). Moreover, our results
indicate that the pioglitazone protective effect depends on
mitochondrial function: pioglitazone was unable to protect
glucose-deprived cells in the presence of malonate, a reversible
mitochondrial Complex II inhibitor, while significantly potentiated
the protective effect of pyruvate against GD plus malonate.
Notably, in our experiments pioglitazone did not significantly
change both basal SDH activity and mitochondrial membrane
potential, thereby suggesting that mitochondrial biogenesis does
not significantly change basal mitochondrial activity, while
increases cell resistance against GD-induced cell loss. Overall
these data suggest that PPARg agonists, through the induction of
PGC-1a promote mitochondrial biogenesis and this action may
contribute to the cytoprotective effects exerted by these drugs.
This hypothesis is in agreement with recent findings showing that
in human umbilical vein endothelial cells pioglitazone and
ciglitazone (another PPARg agonist) induce PGC-1a, promote
mitochondrial biogenesis; effects that may contribute to the
prevention of diabetic vascular complication (Fujisawa et al.,
2009).
Although the mechanism(s) through which the increased
mitochondrial cell content exerts protective effects remain to be
explored, some hypothesis may be proposed. Mitochondria, as
the site of oxidative phosphorylation, provide a highly efficient
route to generate ATP from energy-rich molecules. Thus, it is
reasonable to suppose that cells with increased mitochondrial
content could better tolerate the impairment of energetic
homeostasis caused by GD. Moreover, mitochondria biogenesis
can increase cell resistance against noxious stimuli by mechan-
isms other than those related to ATP synthesis. Mitochondria
possess an high capacity to buffer much of the cytosolic Ca2+
that enter the cells for example during excitotoxic insults
(White and Reynolds, 1996; Nicholls and Budd, 2000), they
maintain physiological levels of NAD+ during genotoxic stress
(i.e. those produced by ROS and PARP-1 activation) and promote
cell survival by the recently defined ‘‘mitochondrial oasis effect’’
(Yang et al., 2007). Therefore, an increased mitochondrial cell
content could exert neuroprotective effects through multiple
mechanisms.
In conclusion, our results show that prolonged exposure of SH-
SY5Y neuronal-like cells to nanomolar pioglitazone or rosiglita-
zone concentrations increases mitochondrial cell content by up-
regulating PGC-1a expression. This effect provides a plausible
mechanism that can contribute to the protective effects exerted by
the drug in ourmodel of GD-induced cell death.Moreover, our data
rise the possibility that mitochondrial biogenesis could be a
potential protectivemechanism of PPARg agonists. Further studies
could clarify the relevance of these findings.
G. Miglio et al. / Neurochemistry International 55 (2009) 496–504 503Acknowledgements
We thank Dr. C. Leo for help with the mitochondrial potential
experiments. This research was supported by grants from the
University of Turin (ex-60%), Regione Piemonte (2007) and
Ministry of Education, University and Research (PRIN 2007).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.neuint.2009.05.001.
References
Aoun, P.,Watson, D.G., Simpkins, J.W., 2003. Neuroprotective effects of PPARgamma
agonists against oxidative insults in HT-22 cells. Eur. J. Pharmacol. 472, 65–71.
Ballesteros, J.R., Mishra, O.P., McGowan, J.E., 2003. Alterations in cerebral mito-
chondria during acute hypoglycemia. Biol. Neonat. 84, 159–163.
Beal, M.F., 2005. Energetics in the pathogenesis of neurodegenerative diseases.
Trends Neurosci. 23, 298–304.
Beal, M.F., Brouillet, E., Jenkins, B., Henshaw, R., Rosen, B., Hyman, B.T., 1993. Age-
dependent striatal excitotoxic lesions produced by the endogenous mitochon-
drial inhibitor malonate. J. Neurochem. 61, 1147–1150.
Berger, J., Moller, D.E., 2002. Themechanisms of action of PPARs. Annu. Rev.Med. 53,
409–435.
Breidert, T., Callebert, J., Heneka, M.T., Landreth, G., Launay, J.M., Hirsch, E.C., 2002.
Protective action of the peroxisome proliferator-activated receptor-gamma
agonist pioglitazone in a mouse model of Parkinson’s disease. J. Neurochem.
82, 615–624.
Budde, K., Neumayer, H.H., Fritsche, L., Sulowicz, W., Stompoˆr, T., Eckland, D., 2003.
The pharmacokinetics of pioglitazone in patients with impaired renal function.
Br. J. Clin. Pharmacol. 55, 368–374.
Colca, J.R., McDonald, W.G., Waldon, D.J., Leone, J.W., Lull, J.M., Bannow, C.A., Lund,
E.T., Mathews, W.R., 2004. Identification of a novel mitochondrial protein
(‘‘mitoNEET’’) cross-linked specifically by a thiazolidinedione photoprobe.
Am. J. Physiol. Endocrinol. Metab. 286, E252–E260.
Culman, J., Zhao, Y., Gohlke, P., Herdegen, T., 2007. PPAR-gamma: therapeutic target
for ischemic stroke. Trends Pharmacol. Sci. 28, 244–249.
de la Monte, S.M., Wands, J.R., 2006. Molecular indices of oxidative stress and
mitochondrial dysfunction occur early and often progress with severity of
Alzheimer’s disease. J. Alzheimers Dis. 9, 167–181.
Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J., Schulz, J.B., 2004. Protection by
pioglitazone in the MPTPmodel of Parkinson’s disease correlates with I kappa B
alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88,
494–501.
Dello Russo, C., Gavrilyuk, V., Weinberg, G., Almeida, A., Bolanos, J.P., Palmer, J.,
Pelligrino, D., Galea, E., Feinstein, D.L., 2003. Peroxisome proliferator-activated
receptor gamma thiazolidinedione agonists increase glucose metabolism in
astrocytes. J. Biol. Chem. 278, 5828–5836.
Fuenzalida, K., Quintanilla, R., Ramos, P., Piderit, D., Fuentealba, R.A., Martinez, G.,
Inestrosa, N.C., Bronfman, M., 2007. Peroxisome proliferator-activated receptor
gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces
mitochondrial stabilization and protection against oxidative stress and apop-
tosis. J. Biol. Chem. 282, 37006–37015.
Fujisawa, K., Nishikawa, T., Kukidome, D., Imoto, K., Yamashiro, T., Motoshima, H.,
Matsumura, T., Araki, E., 2009. TZDs reduce mitochondrial ROS production and
enhance mitochondrial biogenesis. Biochem. Biophys. Res. Commun. 379, 43–
48.
Ghosh, S., Patel, N., Rahn, D., McAllister, J., Sadeghi, S., Horwitz, G., Berry, D.,Wang,
K.X., Swerdlow, R.H., 2007. The thiazolidinedione pioglitazone alters mito-
chondrial function in human neuron-like cells. Mol. Pharmacol. 71, 1695–
1702.
Gomez-Lazaro, M., Galindo, M.F., Melero-Fernandez de Mera, R.M., Fernandez-
Go´mez, F.J., Concannon, C.G., Segura, M.F., Comella, J.X., Prehn, J.H., Jordan, J.,
2007. Reactive oxygen species and p38 mitogen-activated protein kinase
activate Bax to induce mitochondrial cytochrome c release and apoptosis in
response to malonate. Mol. Pharmacol. 71, 736–743.
Hondares, E., Mora, O., Yubero, P., Rodriguez de la Concepcio´n, M., Iglesias, R., Giralt,
M., Villarroya, F., 2006. Thiazolidinediones and rexinoids induce peroxisome
proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an
autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxi-
some proliferator-activated receptor-gamma coactivation. Endocrinology 147,
2829–2838.
Jung, T.W., Lee, J.Y., Shim, W.S., Kang, E.S., Kim, S.K., Ahn, C.W., Lee, H.C., Cha, B.S.,
2007. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against
MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and
ROS production. J. Neurol. Sci. 253, 53–60.
Kauppinen, R.A., Nicholls, D.G., 1986. Synaptosomal bioenergetics. The role of
glycolysis, pyruvate oxidation and responses to hypoglycaemia. Eur. J. Biochem.
158, 159–165.
Kiaei, M., Kipiani, K., Chen, J., Calingasan, N.Y., Beal, M.F., 2005. Peroxisome
proliferator-activated receptor-gamma agonist extends survival in trans-genic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191,
331–336.
Kim, E.J., Park, K.S., Chung, S.Y., Sheen, Y.Y., Moon, D.C., Song, Y.S., Kim, K.S., Song, S.,
Yun, Y.P., Lee, M.K., Oh, K.W., Yoon, D.Y., Hong, J.T., 2003. Peroxisome prolif-
erator-activated receptor-gamma activator 15-deoxy-delta12,14-prostaglan-
din J2 inhibits neuroblastoma cell growth through induction of apoptosis:
association with extracellular signal-regulated kinase signal pathway. J. Phar-
macol. Exp. Ther. 307, 505–517.
Kobayashi, K., Xin, Y., Ymer, S.I., Werther, G.A., Russo, V.C., 2007. Subtractive
hybridisation screen identifies genes regulated by glucose deprivation in
human neuroblastoma cells. Brain Res. 1170, 129–139.
Ko¨gel, D., Svensson, B., Copanaki, E., Anguissola, S., Bonner, C., Thurow, N., Gudorf,
D., Hetschko, H., Mu¨ller, T., Peters, M., Ko¨nig, H.G., Prehn, J.H., 2006. Induction
of transcription factor CEBP homology protein mediates hypoglycaemia-
induced necrotic cell death in human neuroblastoma cells. J. Neurochem.
99, 952–964.
Maeshiba, Y., Kiyota, Y., Yamashita, K., Yoshimura, Y., Motohashi, M., Tanayama, S.,
1997. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and
monkeys. Arzneimittelforschung 47, 29–35.
Moreno, S., Farioli-Vecchioli, S., Ceru`, M.P., 2004. Immunolocalization of peroxi-
some proliferator-activated receptors and retinoid X receptors in the adult rat
CNS. Neuroscience 123, 131–145.
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65,
55–63.
Nicholls, D.G., Budd, S.L., 2000. Mitochondria and neuronal survival. Physiol. Rev.
80, 315–360.
Niemi, M., Backman, J.T., Neuvonen, P.J., 2004. Effects of trimethoprim and rifampin
on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Clin. Pharmacol. Ther. 76, 239–249.
Nisoli, E., Clementi, E., Paolucci, C., Cozzi, V., Tonello, C., Sciorati, C., Bracale, R.,
Valerio, A., Francolini, M., Moncada, S., Carruba, M.O., 2003. Mitochondrial
biogenesis in mammals: the role of endogenous nitric oxide. Science 299,
896–899.
Paddock, M.L., Wiley, S.E., Axelrod, H.L., Cohen, A.E., Roy, M., Abresch, E.C., Capraro,
D., Murphy, A.N., Nechushtai, R., Dixon, J.E., Jennings, P.A., 2007. MitoNEET is a
uniquely folded 2Fe2S outer mitochondrial membrane protein stabilized by
pioglitazone. Proc. Natl. Acad. Sci. U.S.A. 104, 14342–21437.
Pagel-Langenickel, I., Bao, J., Joseph, J.J., Schwartz, D.R., Mantell, B.S., Xu, X., Ragha-
vachari, N., Sack,M.N., 2008. PGC-1a integrates insulin signaling,mitochondrial
regulation, and bioenergetic function in skeletal muscle. J. Biol. Chem. 283,
22464–22472.
Puigserver, P., Spiegelman, B.M., 2003. Peroxisome proliferator-activated receptor-
gamma coactivator 1 alpha (PGC-1alpha): transcriptional coactivator and
metabolic regulator. Endocr. Rev. 4, 78–90.
Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M., Spiegelman, B.M., 1998. A
cold-inducible coactivator of nuclear receptors linked to adaptive thermogen-
esis. Cell 92, 829–839.
Rao, K.V., Norenberg, M.D., 2004. Manganese induces the mitochondrial perme-
ability transition in cultured astrocytes. J. Biol. Chem. 279, 32333–32338.
Rong, J.X., Qiu, Y., Hansen, M.K., Zhu, L., Zhang, V., Xie, M., Okamoto, Y., Mattie, M.D.,
Higashiyama, H., Asano, S., Strum, J.C., Ryan, T.E., 2007. Adipose mitochondrial
biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by
rosiglitazone. Diabetes 56, 1751–1760.
Russo, V.C., Kobayashi, K., Najdovska, S., Baker, N.L., Werther, G.A., 2004. Neuronal
protection from glucose deprivation via modulation of glucose transport and
inhibition of apoptosis: a role for the insulin-like growth factor system. Brain
Res. 1009, 40–53.
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., Sawada,
H., 2000. Activation of human peroxisome proliferator-activated receptor
(PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278, 704–
711.
Schu¨tz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G.E.,
Schu¨rmann, B., Zimmer, A., Heneka, M.T., 2005. The oral antidiabetic pioglita-
zone protects from neurodegeneration and amyotrophic lateral sclerosis-like
symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25,
7805–7812.
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Ja¨ger, S., Handschin, C., Zheng,
K., Lin, J., Yang, W., Simon, D.K., Bachoo, R., Spiegelman, B.M., 2006. Suppression
of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional
coactivators. Cell 127, 397–408.
Strum, J.C., Shehee, R., Virley, D., Richardson, J., Mattie, M., Selley, P., Ghosh, S., Nock,
C., Saunders, A., Roses, A., 2007. Rosiglitazone inducesmitochondrial biogenesis
in mouse brain. J. Alzheimers Dis. 11, 45–51.
Suh, S.W., Gum, E.T., Hamby, A.M., Chan, P.H., Swanson, R.A., 2007a. Hypoglycemic
neuronal death is triggered by glucose reperfusion and activation of neuronal
NADPH oxidase. J. Clin. Invest. 117, 910–918.
Suh, S.W., Hamby, A.M., Swanson, R.A., 2007b. Hypoglycemia, brain energetics, and
hypoglycemic neuronal death. Glia 55, 1280–1286.
Valentiner, U., Carlsson, M., Erttmann, R., Hildebrandt, H., Schumacher, U., 2005.
Ligands for the peroxisome proliferator-activated receptor-gamma have inhi-
bitory effects on growth of human neuroblastoma cells in vitro. Toxicology 213,
157–168.
White, R.J., Reynolds, I.J., 1996. Mitochondrial depolarization in glutamate-stimu-
lated neurons: an early signal specific to excitotoxin exposure. J. Neurosci. 16,
5688–5697.
G. Miglio et al. / Neurochemistry International 55 (2009) 496–504504Willson, T.M., Cobb, J.E., Cowan, D.J., Wiethe, R.W., Correa, I.D., Prakash, S.R., Beck,
K.D., Moore, L.B., Kliewer, S.A., Lehmann, J.M., 1996. The structure–activity
relationship between peroxisome proliferator-activated receptor gamma agon-
ism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39,
665–668.
Wilson-Fritch, L., Nicoloro, S., Chouinard, M., Lazar, M.A., Chui, P.C., Leszyk, J.,
Straubhaar, J., Czech, M.P., Corvera, S., 2004. Mitochondrial remodeling in
adipose tissue associated with obesity and treatment with rosiglitazone. J. Clin.
Invest. 114, 1281–1289.
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A.,
Cinti, S., Lowell, B., Scarpulla, R.C., Spiegelman, B.M., 1999. Mechanisms con-
trolling mitochondrial biogenesis and respiration through the thermogenic
coactivator PGC-1. Cell 98, 115–124.Yang, H., Yang, T., Baur, J.A., Perez, E., Matsui, T., Carmona, J.J., Lamming, D.W.,
Souza-Pinto, N.C., Bohr, V.A., Rosenzweig, A., de Cabo, R., Sauve, A.A., Sinclair,
D.A., 2007. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival.
Cell 130, 1095–1107.
Yki-Ja¨rvinen, H., 2004. Thiazolidinediones. N. Engl. J. Med. 351, 1106–1118.
Zhao, Y., Patzer, A., Herdegen, T., Gohlke, P., Culman, J., 2006. Activation of cerebral
peroxisome proliferator-activated receptors gamma promotes neuroprotection
by attenuation of neuronal cyclooxygenase-2 overexpression after focal cere-
bral ischemia in rats. FASEB J. 20, 1162–1175.
Zimmermann, M., Gardoni, F., Marcello, E., Colciaghi, F., Borroni, B., Padovani, A.,
Cattabeni, F., Di Luca, M., 2004. Acetylcholinesterase inhibitors increase
ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J.
Neurochem. 90, 1489–1499.
